Search

Your search keyword '"LAFAGE POCHITALOFF, M"' showing total 16 results
Start Over Author "LAFAGE POCHITALOFF, M" Database OpenAIRE
16 results on '"LAFAGE POCHITALOFF, M"'

1. B-Cell Acute Lymphoblastic Leukemia (B-ALL) with T (5;14)(Q31;Q32);IGH-IL3 Rearrangement and Eosinophilia: A Peculiar IGH-Rearranged B-ALL

Author

Fournier, B., Balducci, E., Duployez, N., Clappier, E., Cuccuini, W., Cavé, H., Colomb, E. Bottollier-Lemallaz, Nebral, K., Derrieux, C., Cabannes-Hamy, A., Etancelin, P., Fenneteau, O., Gourmel, A., Loosveld, Marie, Gerard, M., Nadal, N., Reismueller, B., Attarbaschi, A., Lafage-Pochitaloff, M., Baruchel, A., Génétique des maladies multifactorielles (GMM), Université de Lille, Droit et Santé-Centre National de la Recherche Scientifique (CNRS), Centre d'Immunologie de Marseille - Luminy (CIML), Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Institut de minéralogie, de physique des matériaux et de cosmochimie (IMPMC), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut de recherche pour le développement [IRD] : UR206-Muséum national d'Histoire naturelle (MNHN)-Centre National de la Recherche Scientifique (CNRS), St. Anna Children's Hospital, AP-HP Hôpital universitaire Robert-Debré [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Muséum national d'Histoire naturelle (MNHN)-Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut de recherche pour le développement [IRD] : UR206-Centre National de la Recherche Scientifique (CNRS), and Saint Anna Children's Hospital [Vienne] = St Anna Kinderspital (St. Anna Children's Hospital)

Subjects
[SDV.IMM]Life Sciences [q-bio]/Immunology
Published
2019

2. Characterization of acute promyelocytic leukemia cases lacking the classic t(15;17)

Author

Grimwade, D., Biondi, A., Mozziconacci, M.J., Hagemeijer, A., Berger, R.A., Neat, M., Howe, K., Dastugue, N., Jansen, J.H., Radford-Weiss, I., Lo Coco, F., Lessard, M., Hernandez, J.M., Delabesse, E., Head, D., Liso, V., Sainty, D., Flandrin, G., Solomon, E., Birg, F., and Lafage-Pochitaloff, M.

Subjects
Hematopoiesis and stem cell transplantation
Abstract

Item does not contain fulltext

Published
2000

3. t(8;21)(q22;q22) with the AML1-ETO fusion gene transcript - in:'Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program'

Author

Aerts, J. L. E., Grimwade, D., Vandekerckhove, P., Navarrete, A., Flora, R., Krauter, J., Heil, G., Viehmann, S., Preudhomme, C., GRARDEL DUFLOS, N., Pane, F., Intrieri, Mariano, Salvatore, F., Cross, N., Kaeda, J., Malec, M., Porwitt, A., Toyron, Y., Mozziconacci, Mj, and LAFAGE POCHITALOFF, M.

Published
2003

6. Reciprocal translocations in breast tumor cell lines: Cloning of a t(3;20) that targets the FHIT gene

Author

Popovici, C., Basset, C., Bertucci, F., Orsetti, A., Adelaide, J., Mozziconacci, M. J., Conte, N., Murati, A., Ginestier, C., Charafe-Jauffret, E., Ethier, S. P., Lafage-Pochitaloff, M., Theillet, C., Birnbaum, D., Chaffanet, M., Centre de résonance magnétique biologique et médicale (CRMBM), Aix Marseille Université (AMU)-Assistance Publique - Hôpitaux de Marseille (APHM)-Centre National de la Recherche Scientifique (CNRS), Sol Agro et hydrosystème Spatialisation (SAS), Institut National de la Recherche Agronomique (INRA)-AGROCAMPUS OUEST, Institut de Biologie du Développement de Marseille (IBDM), Aix Marseille Université (AMU)-Centre National de la Recherche Scientifique (CNRS), Centre de Recherche en Cancérologie de Marseille (CRCM), Aix Marseille Université (AMU)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC), Institut de Génétique Moléculaire de Montpellier (IGMM), Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS), Cancérologie (Inserm U599/IPC), Université de la Méditerranée - Aix-Marseille 2-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM), Aix Marseille Université (AMU)-Collège de France (CdF)-Centre National de la Recherche Scientifique (CNRS), Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Aix Marseille Université (AMU), Centre National de la Recherche Scientifique (CNRS)-Université de Montpellier (UM), Cancérologie, Université de la Méditerranée - Aix-Marseille 2-Institut National de la Santé et de la Recherche Médicale (INSERM), and Institut national d'enseignement supérieur pour l'agriculture, l'alimentation et l'environnement (Institut Agro)-Institut national d'enseignement supérieur pour l'agriculture, l'alimentation et l'environnement (Institut Agro)

Subjects
[SDV.BBM]Life Sciences [q-bio]/Biochemistry, Molecular Biology, comparative genomic hybridization clonal chromosome-abnormalities molecular cytogenetic analysis DNA amplification gamma-heregulin deficient mice cancer carcinomas expression region
Abstract

All molecular alterations that lead to breast cancer are not precisely known. We are evaluating the frequency and consequences of reciprocal translocations in breast cancer. We surveyed 15 mammary cell lines by multicolor fluorescence in situ hybridization (M-FISH). We identified nine apparently reciprocal translocations. Using mBanding FISH and FISH with selected YAC clones, we identified the breakpoints for four of them, and cloned the t(3;20)(p 14;p 11) found in the BrCa-MZ-02 cell line. We found that the breakpoint targets the potential tumor-suppressor gene FHIT (fragile histidine triad) in the FRA3B region; it is accompanied by homozygous deletion of exon 5 of the gene and absence of functional FHIT and fusion transcripts, which leads to the loss of FHIT protein expression. Additional experiments using comparative genomic hybridization provided further information on the genomic context in which the t(3;20)(p 14;p 11) reciprocal translocation was found. (C) 2002 Wiley-Liss, Inc.

Published
2002

7. Identification of a novel CBFB-MYH11 transcript: implications for RT-PCR diagnosis

Author

Reijden, B.A. van der, Wit, L. de, Poel, S.C. van der, Luiten, E.B., Lafage-Pochitaloff, M., Dastugue, N., Gabert, J., Lowenberg, B., Jansen, J.H., and Hematology

Subjects
CHL
Abstract

Item does not contain fulltext INTRODUCTION:: The chromosome rearrangements inv(16)(p13q22) or t(16;16)(p13;q22) are present in approximately 10% of all cases with de novo acute myeloid leukemia and define a subgroup with a favorable prognosis. Both aberrations result in a CBFB-MYH11 fusion gene that can be detected by RT-PCR. PATIENTS AND METHODS:: To date, a total of 10 different in-frame CBFB-MYH11 fusion transcripts have been identified. A newly described transcript can not be amplified with the commonly used PCR primers since the MYH11 junction is located outside the amplified region (MYH11 cDNA position 2134). RESULTS:: We describe here a robust two-step RT-PCR assay that reliably detects all known CBFB-MYH11 transcripts types, including the new variant. CONCLUSION:: Because all previously established RT-PCR protocols may miss the new CBFB-MYH11 transcript, we propose to use the improved RT-PCR approach described here for the reliable detection of all known CBFB-MYH11 fusion transcripts.

Published
2001

15. Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosome-positive ALL

Author

Magda Alexis, Norbert Ifrah, Laurent Sutton, Bruno Lioure, Patrice Chevallier, Jean-Michel Cayuela, Carlo Gambacorti Passerini, Valérie Robin, André Delannoy, José Fernandes, Françoise Huguet, Oumedaly Reman, Philippe Rousselot, Laure Morisset, Thibaut Leguay, Sandrine Hayette, Anne Banos, Caroline Bonmati, marie Magdelaine Coude, Philippe Agape, Renato Bassan, Xavier Thomas, Sylvie Glaisner, Celia Salanoubat, Josep M. Ribera, Dieter Hoelzer, Anne Bornand, Heike Pfeifer, Oliver G. Ottmann, Eric Jourdan, Marina Lafage-Pochitaloff, Marc Delord, Mathilde Hunault, Christian Berthou, Nicola Gökbuget, Hervé Dombret, Le Collège d'études mondiales/FMSH, Fondation Maison des sciences de l'homme (FMSH), Laboratoire Central d'Anatomie et de Cytologie Pathologiques [Hôpital Edouard Herriot - HCL], Hôpital Edouard Herriot [CHU - HCL], Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL), Centre de Recherche en Cancérologie de Lyon (UNICANCER/CRCL), Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Hôpital Purpan [Toulouse], CHU Toulouse [Toulouse], CHU Bordeaux [Bordeaux], Centre d'investigation clinique en cancérologie (CI2C), Centre hospitalier universitaire de Nantes (CHU Nantes), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Centre Hospitalier Régional d'Orléans (CHRO), Lymphocyte B et Auto-immunité (LBAI), Université de Brest (UBO)-Institut Brestois Santé Agro Matière (IBSAM), Université de Brest (UBO)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Hospitalier Régional Universitaire de Brest (CHRU Brest), Centre Hospitalier Saint Jean de Perpignan, Hôpital d'Argenteuil, Hôpital de Bayonne, CH de la Côte Basque, Institut d'Hématologie de Basse-Normandie (IHBN), Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU)-CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Tumorothèque de Caen Basse-Normandie (TCBN)-Centre Régional de Lutte contre le Cancer François Baclesse [Caen] (UNICANCER/CRLC), UNICANCER-Tumorothèque de Caen Basse-Normandie (TCBN)-Normandie Université (NU)-UNICANCER, CHU Strasbourg, Hospices Civils de Lyon (HCL), Assistance Publique - Hôpitaux de Marseille (APHM), Institut Universitaire d'Hématologie (IUH), Université Paris Diderot - Paris 7 (UPD7), Hôpital Saint-Louis, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7), Centre de Recherche en Cancérologie de Lyon (CRCL), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP), Centre Hospitalier Régional d'Orléans (CHR), Université de Brest (UBO)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Brestois Santé Agro Matière (IBSAM), Université de Brest (UBO), Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Tumorothèque de Caen Basse-Normandie (TCBN)-Centre Régional de Lutte contre le Cancer François Baclesse (CRLC François Baclesse ), Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Université Paris Diderot - Paris 7 (UPD7), Rousselot, P, Coudé, M, Gokbuget, N, Gambacorti Passerini, C, Hayette, S, Cayuela, J, Huguet, F, Leguay, T, Chevallier, P, Salanoubat, C, Bonmati, C, Alexis, M, Hunault, M, Glaisner, S, Agape, P, Berthou, C, Jourdan, E, Fernandes, J, Sutton, L, Banos, A, Reman, O, Lioure, B, Thomas, X, Ifrah, N, Lafage-Pochitaloff, M, Bornand, A, Morisset, L, Robin, V, Pfeifer, H, Delannoy, A, Ribera, J, Bassan, R, Delord, M, Hoelzer, D, Dombret, H, and Ottmann, O

Subjects
Male, Oncology, Survival, Clinical Trials and Observations, diagnosis, medicine.medical_treatment, Dasatinib, Fusion Proteins, bcr-abl, Hematopoietic stem cell transplantation, Comorbidity, Biochemistry, Polymerase Chain Reaction, Dexamethasone, 0302 clinical medicine, Maintenance therapy, Belgium, Germany, hemic and lymphatic diseases, Philadelphia Chromosome, genetics, Prospective Studies, Aged, 80 and over, Leukemia, Cytarabine, Hematopoietic Stem Cell Transplantation, Hematology, Middle Aged, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Prognosis, 3. Good health, Italy, Vincristine, 030220 oncology & carcinogenesis, Medicine, Female, France, medicine.drug, Risk, Adult, medicine.medical_specialty, Patients, Immunology, Antineoplastic Agents, [SDV.CAN]Life Sciences [q-bio]/Cancer, 03 medical and health sciences, Internal medicine, medicine, Humans, Asparaginase, Dasatinib, TKI, Ph+ ALL, Protein Kinase Inhibitors, Molecular Biology, Aged, Chemotherapy, therapy, business.industry, Cell Biology, R1, Surgery, Transplantation, Imatinib mesylate, Methotrexate, Mutation, business, Laboratories, 030215 immunology, transplantation, Stem Cell Transplantation
Abstract

International audience; Prognosis of Philadelphia-positive (Ph(+)) acute lymphoblastic leukemia (ALL) in the elderly has improved during the imatinib era. We investigated dasatinib, another potent tyrosine kinase inhibitor, in combination with low-intensity chemotherapy. Patients older than age 55 years were included in the European Working Group on Adult ALL (EWALL) study number 01 for Ph(+) ALL (EWALL-PH-01 international study) and were treated with dasatinib 140 mg/day (100 mg/day over 70 years) with intrathecal chemotherapy, vincristine, and dexamethasone during induction. Patients in complete remission continued consolidation with dasatinib, sequentially with cytarabine, asparaginase, and methotrexate for 6 months. Maintenance therapy was dasatinib and vincristine/dexamethasone reinductions for 18 months followed by dasatinib until relapse or death. Seventy-one patients with a median age of 69 years were enrolled; 77% had a high comorbidity score. Complete remission rate was 96% and 65% of patients achieved a 3-log reduction in BCR-ABL1 transcript levels during consolidation. Only 7 patients underwent allogeneic hematopoietic stem cell transplantation. At 5 years, overall survival was 36% and up to 45% taking into account deaths unrelated to disease or treatment as competitors. Thirty-six patients relapsed, 24 were tested for mutation by Sanger sequencing, and 75% were T315I-positive. BCR-ABL1(T315I) was tested by allele-specific oligonucleotide reverse transcription-quantitative polymerase chain reaction in 43 patients and detection was associated with short-term relapses. Ten patients (23%) were positive before any therapy and 8 relapsed, all with this mutation. In conclusion, dasatinib combined with low-intensity chemotherapy was well-tolerated and gave long-term survival in 36% of elderly patients with Ph(+) ALL. Monitoring of BCR-ABL1(T315I) from diagnosis identified patients with at high risk of early relapse and may help to personalize therapy

Published
2016

16. Genomic gain at 6p21: a new cryptic molecular rearrangement in secondary myelodysplastic syndrome and acute myeloid leukemia

Author

Silvia Romoli, Anna Aventin, Barbara Crescenzi, Peter Marynen, Nicoletta Testoni, Caterina Matteucci, E. Di Bona, M F Martelli, R La Starza, Marina Lafage-Pochitaloff, Anna Locasciulli, Stefania Ciolli, Christina Mecucci, Valentina Pierini, Constantina Sambani, La Starza R, Aventin A, Matteucci C, Crescenzi B, Romoli S, Testoni N, Pierini V, Ciolli S, Sambani C, Locasciulli A, Di Bona E, Lafage-Pochitaloff M, Martelli MF, Marynen P, and Mecucci C.

Subjects
Adult, Male, Cancer Research, Biology, Sensitivity and Specificity, Translocation, Genetic, Fanconi anemia, hemic and lymphatic diseases, medicine, Secondary Acute Myeloid Leukemia, Humans, In Situ Hybridization, Fluorescence, Aged, Genetics, Aged, 80 and over, medicine.diagnostic_test, Myelodysplastic syndromes, Secondary Myelodysplastic Syndrome, Myeloid leukemia, Neoplasms, Second Primary, Hematology, Gene rearrangement, Middle Aged, medicine.disease, Oncology, Leukemia, Myeloid, Myelodysplastic Syndromes, Acute Disease, Cytogenetic Analysis, Chromosomes, Human, Pair 6, Female, Fluorescence in situ hybridization, Comparative genomic hybridization
Abstract

Fluorescence in situ hybridization and comparative genomic hybridization characterized 6p rearrangements in eight primary and in 10 secondary myeloid disorders (including one patient with Fanconi anemia) and found different molecular lesions in each group. In primary disorders, 6p abnormalities, isolated in six patients, were highly heterogeneous with different breakpoints along the 6p arm. Reciprocal translocations were found in seven. In the 10 patients with secondary acute myeloid leukemia/myelodysplastic syndrome (AML/MDS), the short arm of chromosome 6 was involved in unbalanced translocations in 7. The other three patients showed full or partial trisomy of the 6p arm, that is, i(6)(p10) (one patient) and dup(6)(p) (two patients). In 5/7 patients with unbalanced translocations, DNA sequences were overrepresented at band 6p21 as either cryptic duplications (three patients) or cryptic low-copy gains (two patients). In the eight patients with cytogenetic or cryptic 6p gains, we identified a common overrepresented region extending for 5-6 megabases from the TNF gene to the ETV-7 gene. 6p abnormalities were isolated karyotype changes in four patients. Consequently, in secondary AML/MDS, we hypothesize that 6p gains are major pathogenetic events arising from acquired and/or congenital genomic instability.

Published
2006

Catalog

Books, media, physical & digital resources
See catalog results